Related Experiment Video
Updated: Jun 7, 2025
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Guillain-Barre syndrome following Pfizer-BioNTech (BNT162b2) vaccination: a case report
Aashutosh Chaudhary1, Shrekshya Khadka2, Aliza Dulal1
1Kathmandu University School of Medical Sciences, Dhulikhel.
Introduction:
Pfizer-BioNTech (BNT162b2) is one of the mRNA vaccines currently approved by the WHO and the Food and Drug Administration (FDA) against COVID-19.
Case Presentation:
Here, the authors report a case of an 8-year-old female with Guillain-Barré syndrome following the second dose of Pfizer-BioNTech (BNT162b2) vaccination requiring respiratory support who was managed with intravenous immunoglobulin.
Discussion:
There have been reports of Guillain-Barré syndrome following the Pfizer-BioNTech vaccination. In the authors' case, as the symptoms of Guillain-Barré syndrome occurred right after the vaccination, there could be an association, and this report can add to the existing literature and raise awareness about the possible adverse effects of the Pfizer-BioNTech vaccination.
Conclusion:
Although most adverse effects following Pfizer-BioNTech (BNT162b2) vaccination have been reported as non-serious, clinicians must be aware of serious adverse effects that, although rare, can follow the administration of Pfizer-BioNTech vaccination and require prompt recognition and management.
